Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives

Bibliography

• Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011;10(3):407-17
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Garcia AA, Vogel C, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat 2013;140(2):341-51
   PubMed Web of Science ®Google Scholar
• Lewis MA, Zhao F, Jones D, et al. Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal versus breast, lung or prostate cancer: results from a prospective multicenter study. J Pain Symptom Manage 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014;155(12):2461-70
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27(19):3109-16
   PubMed Web of Science ®Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29(28):3768-74
   PubMed Web of Science ®Google Scholar
• Carozzi VA, Canta A, Chiorazzi A, Cavaletti G. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 2015;596:90-107
   PubMed Web of Science ®Google Scholar
• Hong JS, Tian J, Wu LH. The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol Tor Ont 2014;21(4):174-80
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 2014;22(8):2261-9
   PubMed Web of Science ®Google Scholar
• Pike CT, Birnbaum HG, Muehlenbein CE, et al. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012;2012:913848
   PubMedGoogle Scholar
• Kim JH, Dougherty PM, Abdi S. Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy. Gynecol Oncol 2015;136(3):453-9
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32(18):1941-67
   PubMed Web of Science ®Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014;3:CD005228
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14(2):162-73
   PubMed Web of Science ®Google Scholar
• Wolf SL, Barton DL, Qin R, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 2012;20(3):625-32
   PubMed Web of Science ®Google Scholar
• De Carvalho Barbosa M, Kosturakis AK, Eng C, et al. A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. Cancer Res 2014;74(21):5955-62
   PubMed Web of Science ®Google Scholar
• Kautio A-L, Haanpää M, Leminen A. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res 2009;29(7):2601-6
   PubMed Web of Science ®Google Scholar
• Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002;98(1-2):195-203
   PubMed Web of Science ®Google Scholar
• Kautio A-L, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35(1):31-9
   PubMed Web of Science ®Google Scholar
• Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012;23(1):200-5
   PubMed Web of Science ®Google Scholar
• Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359-67
   PubMed Web of Science ®Google Scholar
• Balayssac D, Ling B, Ferrier J, et al. Assessment of thermal sensitivity in rats using the thermal place preference test: description and application in the study of oxaliplatin-induced acute thermal hypersensitivity and inflammatory pain models. Behav Pharmacol 2014;25(2):99-111
   PubMed Web of Science ®Google Scholar
• Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007;110(9):2110-18
   PubMed Web of Science ®Google Scholar
• Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009;23(7):555-68
   PubMed Web of Science ®Google Scholar
• Von Delius S, Eckel F, Wagenpfeil S, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007;25(2):173-80
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006;67(12):2253-5
   PubMed Web of Science ®Google Scholar
• Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008;112(12):2802-8
   PubMed Web of Science ®Google Scholar
• Geis C, Beyreuther BK, Stöhr T, Sommer C. Lacosamide has protective disease modifying properties in experimental vincristine neuropathy. Neuropharmacology 2011;61(4):600-7
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hidvégi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010;33(4):839-41
   PubMed Web of Science ®Google Scholar
• Wymer JP, Simpson J, Sen D, Bongardt S; Lacosamide SP742 Study Group. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009;25(5):376-85
   PubMed Web of Science ®Google Scholar
• Flatters SJL, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004;109(1-2):150-61
   PubMed Web of Science ®Google Scholar
• Kawashiri T, Egashira N, Kurobe K, et al. L type Ca2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain 2012;8:7
   PubMed Web of Science ®Google Scholar
• Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011;19(6):833-41
   PubMed Web of Science ®Google Scholar
• Fallon MT, Storey DJ, Krishan A, et al. Cancer treatment-related neuropathic pain: proof of concept study with menthol-a TRPM8 agonist. Support Care Cancer 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ling B, Coudoré F, Decalonne L, et al. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology 2008;55(5):724-8
   PubMed Web of Science ®Google Scholar
• Ling B, Authier N, Balayssac D, et al. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 2007;128(3):225-34
   PubMed Web of Science ®Google Scholar
• Nozaki-Taguchi N, Chaplan SR, Higuera ES, et al. Vincristine-induced allodynia in the rat. Pain 2001;93(1):69-76
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
   PubMed Web of Science ®Google Scholar
• Zhao M, Nakamura S, Miyake T, et al. Pharmacological characterization of standard analgesics on oxaliplatin-induced acute cold hypersensitivity in mice. J Pharmacol Sci 2014;124(4):514-17
   PubMed Web of Science ®Google Scholar
• Deuis JR, Lim YL, Rodrigues de Sousa S, et al. Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin. Neuro-Oncol 2014;16(10):1324-32
   PubMed Web of Science ®Google Scholar
• Thibault K, Calvino B, Rivals I, et al. Molecular mechanisms underlying the enhanced analgesic effect of oxycodone compared to morphine in chemotherapy-induced neuropathic pain. PLoS One 2014;9(3):e91297
   PubMedGoogle Scholar
• Nagashima M, Ooshiro M, Moriyama A, et al. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer 2014;22(6):1579-84
   PubMed Web of Science ®Google Scholar
• Cartoni C, Brunetti GA, Federico V, et al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer 2012;20(10):2621-6
   PubMed Web of Science ®Google Scholar
• Liu Y-C, Wang W-S. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer 2012;118(6):1718-25
   PubMed Web of Science ®Google Scholar
• Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10(5):795-803
   PubMed Web of Science ®Google Scholar
• Zhang H, Boyette-Davis JA, Kosturakis AK, et al. Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. J Pain 2013;14(10):1031-44
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Z, Kim H-S, et al. CD31(+) cell transplantation promotes recovery from peripheral neuropathy. Mol Cell Neurosci 2014;62:60-7
   PubMed Web of Science ®Google Scholar
• Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008;9(5):463-72
   PubMed Web of Science ®Google Scholar
• Massey RL, Kim HK, Abdi S. Brief review: chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions. Can J Anaesth 2014;61(8):754-62
   PubMed Web of Science ®Google Scholar
• Peters CM, Jimenez-Andrade JM, Kuskowski MA, et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007;1168:46-59
   PubMed Web of Science ®Google Scholar
• Zhang H, Yoon S-Y, Zhang H, Dougherty PM. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain 2012;13(3):293-303
   PubMed Web of Science ®Google Scholar
• Robinson CR, Zhang H, Dougherty PM. Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. Neuroscience 2014;274:308-17
   PubMed Web of Science ®Google Scholar
• Cata JP, Weng H-R, Chen J-H, Dougherty PM. Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 2006;138(1):329-38
   PubMed Web of Science ®Google Scholar
• Wang X-M, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59(1):3-9
   PubMed Web of Science ®Google Scholar
• Mika J, Osikowicz M, Makuch W, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007;560(2-3):142-9
   PubMed Web of Science ®Google Scholar
• Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011;152(2):308-13
   PubMed Web of Science ®Google Scholar
• Pevida M, Lastra A, Hidalgo A, et al. Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia. Brain Res Bull 2013;95:21-7
   PubMed Web of Science ®Google Scholar
• Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007;16(7):935-50
   PubMed Web of Science ®Google Scholar
• Sweitzer SM, Pahl JL, DeLeo JA. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci Lett 2006;400(3):258-61
   PubMed Web of Science ®Google Scholar
• Nassini R, Gees M, Harrison S, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011;152(7):1621-31
   PubMed Web of Science ®Google Scholar
• Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85(5):2293-7
   PubMed Web of Science ®Google Scholar
• Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008;29(6):1100-6
   PubMed Web of Science ®Google Scholar
• Zhang H, Dougherty PM. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology 2014;120(6):1463-75
   PubMed Web of Science ®Google Scholar
• Descoeur J, Pereira V, Pizzoccaro A, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. Embo Mol Med 2011;3(5):266-78
   PubMed Web of Science ®Google Scholar
• Sałat K, Cios A, Wyska E, et al. Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. Pharmacol Biochem Behav 2014;122:173-81
   PubMed Web of Science ®Google Scholar
• Trevisan G, Materazzi S, Fusi C, et al. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res 2013;73(10):3120-31
   PubMed Web of Science ®Google Scholar
• Gauchan P, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 2009;458(2):93-5
   PubMed Web of Science ®Google Scholar
• Nieto FR, Entrena JM, Cendán CM, et al. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008;137(3):520-31
   PubMed Web of Science ®Google Scholar
• Hagen NA, du Souich P, Lapointe B, et al. Tetrodotoxin for moderate to severe cancer pain: a randomized, double blind, parallel design multicenter study. J Pain Symptom Manage 2008;35(4):420-9
   PubMed Web of Science ®Google Scholar
• Azevedo MI, Pereira AF, Nogueira RB, et al. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy. Mol Pain 2013;9:53
   PubMed Web of Science ®Google Scholar
• Barrière DA, Rieusset J, Chanteranne D, et al. Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization. Pain 2012;153(3):553-61
   PubMed Web of Science ®Google Scholar
• Erken HA, Koç ER, Yazıcı H, et al. Selenium partially prevents cisplatin-induced neurotoxicity: a preliminary study. Neurotoxicology 2014;42:71-5
   PubMed Web of Science ®Google Scholar
• Babu A, Prasanth KG, Balaji B. Effect of curcumin in mice model of vincristine-induced neuropathy. Pharm Biol 2014;1-11
   Google Scholar
• Al Moundhri MS, Al-Salam S, Al Mahrouqee A, et al. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. J Med Toxicol Off 2013;9(1):25-33
   PubMedGoogle Scholar
• Carozzi VA, Chiorazzi A, Canta A, et al. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 2010;17(4):380-91
   PubMed Web of Science ®Google Scholar
• Lynch JJ, Wade CL, Zhong CM, et al. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 2004;110(1-2):56-63
   PubMed Web of Science ®Google Scholar
• Zhou H-Y, Chen S-R, Pan H-L. Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol 2011;4(3):379-88
   PubMedGoogle Scholar
• Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48(3):328-36
   PubMed Web of Science ®Google Scholar
• Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002;96(5):1053-61
   PubMed Web of Science ®Google Scholar
• Ferrier J, Bayet-Robert M, Pereira B, et al. A polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in rats. PLoS ONE 2013;8(10):e77828
   PubMed Web of Science ®Google Scholar
• Balayssac D, Ferrier J, Pereira B, et al. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. Bmj Open 2015;5(4):e007479
   PubMed Web of Science ®Google Scholar
• Zhang M, Han W, Hu S, Xu H. Methylcobalamin: a potential vitamin of pain killer. Neural Plast 2013;2013:424651
   PubMed Web of Science ®Google Scholar
• Bell RF, Borzan J, Kalso E, Simonnet G. Food, pain, and drugs: does it matter what pain patients eat? Pain 2012;153(10):1993-6
   PubMed Web of Science ®Google Scholar
• Yao J, Ge C, Duan D, et al. Activation of the phase II enzymes for neuroprotection by ginger active constituent 6-dehydrogingerdione in PC12 cells. J Agric Food Chem 2014;62(24):5507-18
   PubMed Web of Science ®Google Scholar
• Ha SK, Moon E, Ju MS, et al. 6-Shogaol, a ginger product, modulates neuroinflammation: a new approach to neuroprotection. Neuropharmacology 2012;63(2):211-23
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322(2):709-20
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, et al. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J Pharmacol Exp Ther 2008;326(2):623-32
   PubMed Web of Science ®Google Scholar
• Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012;203:194-206
   PubMed Web of Science ®Google Scholar
• Xiao WH, Zheng FY, Bennett GJ, et al. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent. paclitaxel. Pain 2009;147(1-3):202-9
   PubMed Web of Science ®Google Scholar
• Rovini A, Carré M, Bordet T, et al. Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol 2010;80(6):884-94
   PubMed Web of Science ®Google Scholar
• Rahn EJ, Deng L, Thakur GA, et al. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Mol Pain 2014;10:27
   PubMed Web of Science ®Google Scholar
• Ward SJ, McAllister SD, Kawamura R, et al. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol 2014;171(3):636-45
   PubMed Web of Science ®Google Scholar
• Uhelski ML, Khasabova IA, Simone DA. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. J Neurophysiol 2015;113(5):1501-10
   PubMed Web of Science ®Google Scholar
• Sasane M, Tencer T, French A, et al. Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review. J Support Oncol 2010;8(6):e15-21
   PubMedGoogle Scholar
• Cavaletti G. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist 2011;16(12):1667-8
   PubMed Web of Science ®Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10(12 Pt 1):4055-61
   PubMed Web of Science ®Google Scholar
• Khattak MA. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist 2011;16(12):1780-3
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014;32(10):997-1005
   PubMed Web of Science ®Google Scholar
• Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152(1):14-27
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010;8:18
   PubMed Web of Science ®Google Scholar
• Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother 2010;1(2):94-9
   PubMedGoogle Scholar
• Authier N, Balayssac D, Marchand F, et al. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009;6(4):620-9
   PubMed Web of Science ®Google Scholar